Search results
A cancer drug could give me more time - but my life 'isn't worth the cost'
Metro· 19 hours agoHowever, this week the National Institute for Health and Care Excellence (Nice) published final...
What’s happened to stroke care on NHS Scotland?
The Herald· 20 hours agoAround 15,000 people in Scotland will suffer a stroke each year. Performance against what is known as the stroke bundle was worse in 2022 and 2023 than at "any time since the standards were ...
Pinetree secures $17m to advance TPD development programmes
Pharmaceutical Business Review· 20 hours agoPinetree Therapeutics has secured $17m in a Series A funding round to advance its new multispecific...
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs...
Benzinga via Yahoo Finance UK· 2 days agoOn Tuesday, Merck & Co Inc (NYSE:MRK) reported second-quarter sales of $16.1 billion, up 7%...
AstraZeneca falls after UK drug watchdog blocks NHS access to Enhertu drug
Proactive Financial News· 2 days agoAstraZeneca PLC (LSE:AZN) shares fell more than 1.7% on Tuesday after the English healthcare watchdog said that it could not recommend the drug company's...
London open: Stocks fall as BP shines, Diageo tumbles
ShareCast· 2 days agoLondon stocks fell in early trade on Tuesday as investors waded through a barrage of earnings from...
Life-extending breast cancer drug WILL NOT be made available on NHS
Daily Mail· 2 days agoIt then paused its appraisal in December during talks with pharmaceutical companies Daiichi Sankyo...
Pharma companies less concerned after hearing from US on negotiated prices for Medicare
Reuters· 2 days agoFour pharmaceutical companies involved in the first U.S. negotiations over prices for the Medicare...
Terminally-ill breast cancer sufferers denied life-extending drug
Daily Telegraph· 3 days agoTalks break down between Nice and pharmaceutical companies over NHS rollout of Enhertu
London close: Stocks finish mixed at start of busy week
ShareCast· 3 days agoLondon stocks closed with mixed results on Monday, reflecting a cautious market sentiment ahead of a...
